Literature DB >> 20403393

Extracellular neurosin degrades α-synuclein in cultured cells.

Harutsugu Tatebe1, Yoshihisa Watanabe, Takashi Kasai, Toshiki Mizuno, Masanori Nakagawa, Masaki Tanaka, Takahiko Tokuda.   

Abstract

Neurosin, also called kallikrein 6, is a trypsin-like serine protease predominantly expressed in the central nervous system. Neurosin may degrade alpha-synuclein, a major component of the Lewy bodies commonly observed in dopaminergic neurons of patients with sporadic Parkinson's disease. In the present study, we investigated the localization and proteolytic activity of human neurosin using cultured cells to elucidate the physiological role of this enzyme at the cellular level. Heterologous expression of pre-pro-neurosin was localized to the endoplasmic reticulum and secreted. The proteolytic activity of neurosin was analyzed by zymography and fluorescent substrate, and showed that extracellular neurosin had protease activity but intracellular neurosin did not. We also coexpressed alpha-synuclein with neurosin and demonstrated that alpha-synuclein was not cleaved within cells, but extracellular alpha-synuclein was degraded by secreted neurosin. These findings suggest that neurosin targets the extracellular alpha-synuclein. Copyright 2010 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20403393     DOI: 10.1016/j.neures.2010.04.008

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  37 in total

1.  Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.

Authors:  Brian Spencer; Sarah Michael; Jay Shen; Kori Kosberg; Edward Rockenstein; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

Review 2.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

Review 3.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

4.  Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.

Authors:  Maroulio Talieri; Marita Zoma; Marina Devetzi; Andreas Scorilas; Alexandros Ardavanis
Journal:  Tumour Biol       Date:  2012-04-03

Review 5.  Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy.

Authors:  E Valera; G Monzio Compagnoni; E Masliah
Journal:  Neuropathol Appl Neurobiol       Date:  2016-02       Impact factor: 8.090

Review 6.  The emerging role of α-synuclein truncation in aggregation and disease.

Authors:  Zachary A Sorrentino; Benoit I Giasson
Journal:  J Biol Chem       Date:  2020-05-18       Impact factor: 5.157

7.  Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease.

Authors:  Kwang Soo Kim; Yu Ree Choi; Ji-Young Park; Jung-Ho Lee; Dong Kyu Kim; Seung-Jae Lee; Seung R Paik; Ilo Jou; Sang Myun Park
Journal:  J Biol Chem       Date:  2012-05-22       Impact factor: 5.157

Review 8.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

Review 9.  Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease.

Authors:  Sang Myun Park; Kwang Soo Kim
Journal:  Prion       Date:  2012-11-15       Impact factor: 3.931

10.  Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms.

Authors:  Hyesook Yoon; Maja Radulovic; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2018-09-25       Impact factor: 3.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.